- The P-II trial will assess the efficacy & safety of RTX across several dose groups vs PBO in patients with a mod. to sev. OAK pain. The study follows the P-Ib trial results of RTX
- The P-Ib data demonstrated the significant efficacy supporting RTX for long term refractory OA pain, pain relief observed in patients with advanced OA disease, and sustained pain relief last beyond 6 mos.
- The program continues with P-II & P-III trial in larger patient populations, while the P-II trial will be targeted to identify the RP3D. The company has decided to add an active comparator (injectable corticosteroid) in the current trial protocol to give the durability of OA pain relief response
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Analyze Markets